Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins in non-dialysis chronic kidney patients: A double-blind, randomized, placebo-controlled trial

• Main Authors: Amanda de Faria Barros, Natália A. Borges, Lia Sumie Nakao, Carla J. Dolenga, Flavia Lima do Carmo, Dennis de Carvalho Ferreira, Peter Stenvinkel, Peter Bergman, Bengt Lindholm, Denise Mafra
• Format: Article
• Language: English
• Published: Elsevier 2018-07-01
• Series: Journal of Functional Foods
• Subjects: Chronic kidney disease; Cardiovascular disease; Inflammation; Uremic toxins
• Online Access: http://www.sciencedirect.com/science/article/pii/S1756464618302354

Probiotics may mitigate the generation of uremic toxins and inflammatory biomarkers. The aim of this study was to evaluate the effects of probiotics on uremic toxins and inflammatory biomarkers in CKD. In this randomized, double-blind, placebo-controlled trial, 30 patients (63.8 ± 7.5 years, 14 men, mean BMI of 27.2 ± 3.8 kg/m2) were assigned to receive one of two treatments: probiotics (n = 15; Streptococcus thermophilus, Lactobacillus acidophilus and Bifidobacteria longum-90 billion CFU per day) or placebo (n = 15) daily for three months. Plasma uremic toxins were measured using reversed-phase liquid-chromatography (RP-HPLC); choline, betaine and trimethylamine-N-oxide (TMAO) were measured using liquid chromatography–mass spectrometry (LC-MS/MS); and inflammatory biomarkers were measured using ELISA. Uremic toxins were not influenced by the probiotics; however, IL-6 levels increased significantly from 15.6 (14.8–20.8) pg/mL to 23.0 (17.6–29.6) pg/mL, p = 0.01. There was a positive correlation between the levels of p-cresyl sulfate and urea (r = 0.55; p = 0.02) and between TMAO and CRP (r = 0.46; p = 0.05) at baseline. These data suggest that probiotic supplementation did not result in expected benefits for non-dialysis CKD patients.